Lead Product(s) : Bretisilocin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : AbbVie Inc
Deal Size : $1,200.0 million
Deal Type : Acquisition
AbbVie to Acquire Gilgamesh Bretisilocin, a Novel, Investigational Therapy
Details : AbbVie will GM-2505 (bretisilocin) acquire Gilgamesh's lead investigational candidate, currently in development for the treatment of patients with moderate-to-severe major depressive disorder.
Product Name : GM-2505
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 25, 2025
Lead Product(s) : Bretisilocin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : AbbVie Inc
Deal Size : $1,200.0 million
Deal Type : Acquisition